The European drug regulator has called for a review of Sanofi’s multiple sclerosis drug Lemtrada following reports of immune-related conditions and sometimes fatal problems with the heart a
Sanofi and Alnylam have agreed to conclude the research and option phase of their 2014 RNAi therapeutics alliance for developing drugs for rare genetic diseases.
This year’s eyeforpharma Barcelona conference might have seemed all doom and gloom at the outset, with many predicting the downfall of pharma as we know it – but there were plenty of speake